Diametric Capital’s Meridian Bioscience Inc VIVO Stock Holding History

Diametric Capital’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-23,227	Closed	-$732K	–	386
2022 Q3	$732K	Buy	+23,227	New	+$752K	0.37%	99

Other funds holding VIVO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

NAM

Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Diametric Capital's VIVO Position: Q4 2022 in Review

Diametric Capital sold out of Meridian Bioscience Inc (VIVO) in Q4 2022, closing a stake of 23,227 shares — an estimated $732K sold.

Diametric Capital first reported a position in VIVO in Q3 2022 and held it in 1 quarter. The position peaked at $732K in Q3 2022. 218 funds tracked by Wall St. Rank hold VIVO as of Q4 2022.

Diametric Capital reported no remaining Meridian Bioscience Inc position as of Q4 2022 after selling out during the quarter.
Diametric Capital sold 23,227 Meridian Bioscience Inc shares in Q4 2022, an estimated $732K.
Diametric Capital first reported a position in Meridian Bioscience Inc in Q3 2022 and held it in 1 quarter.
Diametric Capital's Meridian Bioscience Inc position peaked at $732K in Q3 2022.
218 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q4 2022.

Based on Diametric Capital's 13F filing for Q4 2022, filed 29 Mar 2023.